England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to achieve significant clinical outcomes.
英格蘭國民健康服務（NHS England）提議分階段推出一種大有前途的減肥藥物提澤帕肽（tirzepatide），以使最有可能取得顯著臨床效果的患者受益。
Tirzepatide, branded as Mounjaro and produced by Eli Lilly And Co (NYSE:LLY), has shown remarkable results in clinical trials. It offers greater weight loss than existing therapies like Novo Nordisk A/S' (NYSE:NVO) and Ozempic (semaglutide).
提澤帕肽以（Mounjaro）的品牌身份由禮來（Eli Lilly And Co，NYSE: LLY）生產，臨床試驗顯示出令人矚目的成果。它提供比諾和諾德製藥（Novo Nordisk A/S，NYSE:NVO）和歐仙匹克（semaglutide）等現有療法更大的減重效果。
In the SURMOUNT-4 trial, patients lost an average of 20.9% of their body weight in 36 weeks.
在SURMOUNt-4試驗中，患者在36周內平均減去體重的20.9%。
Also Read: Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals.
還閱讀：研究顯示，像歐仙匹克（Ozempic）這樣的熱門減肥藥物在臨床試驗承諾與實際應用之間存在差距。
The plan, currently under consultation, aims to test various medication delivery models before expanding its availability.
該計劃目前正在徵求意見，旨在在擴大其可用性之前測試各種藥物交付模式。
Under draft guidance from an independent committee at the National Institute for Health and Care Excellence (NICE), tirzepatide has been recommended for patients living with obesity, with a maximum list price of 122 pounds ($159.6) per month for the highest dose.
根據國家衛生與臨床卓越研究所（NICE）的獨立委員會的初步指導意見，提澤帕肽已被推薦給患有肥胖症的患者，最高服用劑量每月售價122英鎊（159.6美元）。
The phased launch will integrate tirzepatide into community-based services and digital health platforms to expand accessibility.
分階段推出將把提澤帕肽整合到基於社區的服務和互聯網醫療平台中，以擴大可及性。
The rollout will target up to 240,000 people in the first three years and evaluate cost-effective delivery models, including virtual clinics.
推出將瞄準首三年內最多24萬人，並評估成本效益的交付模式，包括虛擬診所。
Eligible patients will be categorized based on their BMI and related health conditions. Initially, those with a BMI above 40 and three or more weight-related conditions, such as hypertension and cardiovascular disease, will qualify.
符合條件的患者將根據其BMI和相關健康狀況進行分類。最初，那些BMI超過40且有三個或更多與體重相關的疾病，如高血壓和心血管疾病的患者將符合條件。
Obesity is a significant challenge for the NHS, with annual treatment costs reaching 11.4 billion pounds ($14.91 billion).
肥胖對英國國民醫療服務是一個重大挑戰，每年的治療成本達到114億英鎊（149.1億美元）。
According to the Health Survey for England 2022, about 64% of adults in the country are overweight or obese.
根據2022年英格蘭衛生調查，該國約64%的成年人超重或肥胖。
The consultation period for the rollout plan is currently open, with final guidance from NICE expected later this year.
展開計劃的諮詢期目前正在進行中，預計英國國家衛生與臨床卓越學院將在年底發佈最終指導意見。
Earlier this week, Eli Lilly announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development, as the company inches closer to becoming the first pharma company in the $1 trillion club.
本週早些時候，禮來宣佈將投資45億美元創建禮來醫藥鑄造廠，這是一家新的先進製造和藥物開發中心，使公司距離成爲第一家入圍萬億美元俱樂部的製藥公司更近一步。
Price Action: LLY stock is down 0.23% at $883.56 at the last check Friday.
股價走勢：LLY股價在上週最後一次檢查時下跌0.23%，報883.56美元。
- Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses.
- 諾和賽/阿斯利康的製造合作伙伴賽默飛世被質疑製造上的疏漏。
Photo via Company
照片來自公司
譯文內容由第三人軟體翻譯。
